Company Overview and News

0
Goldmoney Inc. Reports Record Quarterly Revenue, First-Ever Annual Profit, and 90% Growth in Tangible Capital at Year End Fiscal 2018

2018-06-22 globenewswire
TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- Goldmoney Inc. (TSX:XAU) (“Goldmoney”)(the “Company”), a precious metal financial service and technology company, today announced financial results for the fiscal year ended March 31, 2018. All amounts are expressed in Canadian dollars unless otherwise noted.
BTGDF XAUMF

1
Goldmoney Announces Dealing and Institutional Crypto Custody Partnership with Malbex

2018-06-21 globenewswire
TORONTO, June 21, 2018 (GLOBE NEWSWIRE) -- Goldmoney Inc. (TSX:XAU) (“Goldmoney”) (the “Company”), a precious metal financial service and technology company, today announced a new dealing and third-party custodian relationship with Malbex Resources Inc. (TSXV:COIN) (“COIN”), a merchant banking and financial advisory company focused on investments in cryptocurrency and blockchain sector assets (soon to be renamed COIN Hodl Inc.
BTGDF MXRSF MBG XAUMF

0
Goldmoney Announces Date of Year-End 2018 Earnings Release and Conference Call

2018-06-20 globenewswire
TORONTO, June 20, 2018 (GLOBE NEWSWIRE) -- Goldmoney Inc. (TSX:XAU) (“Goldmoney”) (the “Company”), a precious metal financial service and technology company, will announce year-end 2018 financial results before market open on Friday, June 22.
BTGDF XAUMF

0
Malbex Resources Completes Change of Business to focus on Cryptocurrency and Blockchain Sectors

2018-06-20 globenewswire
TORONTO, June 20, 2018 (GLOBE NEWSWIRE) -- Malbex Resources Inc. ("Malbex" or the "Company") (TSX-V:MBG) is pleased to announce that it has closed its change of business transaction (the "Transaction") pursuant to the policies of the TSX Venture Exchange (the "Exchange") with Samara Capital Inc. ("Samara") and become a merchant banking and financial advisory company focused on the small-cap market, with investments in cryptocurrency and blockchain sectors (the "New Business").
BTGDF MXRSF MBG XAUMF

3
Focused Capital II Corp. Announces Signing of Definitive Business Combination Agreement With Fortress Blockchain Corp. for Proposed Qualifying Transaction

2018-03-22 globenewswire
Focused Capital II Corp. ("Focused Capital II" or the "Company") (TSX-V:FAV.H), a capital pool company pursuant to Policy 2.4 of the TSX Venture Exchange (the "TSX-V"), is pleased to announce that it has entered into a definitive business combination agreement with Fortress Blockchain Corp. ("Fortress Blockchain") effective as of March 21, 2018 (the "Definitive Agreement"), which outlines the terms and conditions pursuant to which Focused Capital II and Fortress Blockchain will complete the transaction that will result in a reverse-takeover of Focused Capital II by the shareholders of Fortress Blockchain (the "Transaction").
FAV.H BTGDF DDAIF XAUMF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...